Pα+ Psychedelic Bulletin #219: Trump Admin Vetoed Compass Priority Voucher; Ibogaine in Focus; Definium Sued; Epstein Files

Policy and business news drive Pα+ Psychedelic Bulletin #219, focusing on drug development timelines, state regulatory movement, and safety concerns. The bulletin reports that the Trump administration vetoed Compass Pathways from receiving a Commissioner’s National Priority Voucher, a change that would have reduced FDA drug review time to around one to two months. The bulletin then highlights ibogaine coverage, including how quickly “ibogaine bills” are moving through state legislatures and why safety and regulation remain central themes. It also notes that ibogaine drug development is still early stage while referencing early Phase 1 data activity by a company involved in ibogaine development. In industry and legal updates, the bulletin covers Definium being sued by a former vendor over alleged trade secret theft. It also links psychedelics to newly released Epstein-related documents and mentions additional state bills expanding the growing psychedelics policy agenda.